Company Profile

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE555.25-4.55 (-0.81 % )
PREV CLOSE (Rs.) 559.80
OPEN PRICE (Rs.) 558.00
BID PRICE (QTY) 557.60 (75 )
OFFER PRICE (QTY) 560.00 (405 )
VOLUME 34555
TODAY'S LOW / HIGH (Rs.)551.25 563.95
52 WK LOW / HIGH (Rs.)483.75 678
NSE555.60 -2.95 (-0.53 % )
PREV CLOSE(Rs.) 558.55
OPEN PRICE (Rs.) 558.70
BID PRICE (QTY) 555.60 (2530 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2416194
TODAY'S LOW / HIGH(Rs.) 551.15 563.95
52 WK LOW / HIGH (Rs.)483.75 678.45

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.54
TTM EPS (Rs.) 18.36
P/E Ratio 30.24
Book Value (Rs.) 186.99
Face Value (Rs.) 2
MCap (Rs. in Mn) 447366.75
Price/Earning (TTM) 21.96
Price/Sales (TTM) 3.99
Price/Book (MRQ) 2.97
PAT Margin (%) 12.83
ROCE (%) 14.03
Incorporation Year : 1935

Management Info :

Y K Hamied - Chairman Umang Vohra - Managing Director

Registered Office :

Address : Cipla House,Peninsula Business Park,Ganpatrao Kadam Marg, Lower Parel,
Mumbai,
Maharashtra-400013

Phone : 022-24826000 / 022-24826951

Website : www.cipla.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX
NEWS More
17Apr04-17-2019$Cipla’s arm to acquire 30% stake in Brandmed Cipla’s arm to acquire 30%

Cipla’s South Africa-based subsidiary--- Cipla Medpro will acquire 30 percent stake in the connected healthcare firm Brandmed (Pty) for an upfront cash consideration of ZAR 65 million (nearly Rs 32 crore).

The company will also pay certain milestone payment for the stake acquisition over a period of three years, subject to meeting agreed profit targets. This transaction will help to transition healthcare from being reactive to a proactive and real-time monitoring model that focuses on promoting wellness instead of managing illness.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla’s South Africa-based subsidiary--- Cipla Medpro will ac..
16Apr04-16-2019$Cipla’s arm inks definitive agreement with Pulmatrix Cipla’s arm inks definitiv

Cipla’s subsidiary -- Cipla Technologies LLC and Pulmatrix, Inc., a clinical stage biopharmaceutical company has entered into a definitive agreement for the co-development and commercialization of Pulmazole (PUR1900) - an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Following the Definitive Agreement, Cipla Technologies will make an upfront payment of $22 million to Pulmatrix in exchange for assignment of all rights for Pulmazole in relation to pulmonary indications to Cipla Technologies. Thereafter, both parties will equally share costs related to the future development and commercialization of Pulmazole, and equally share worldwide free cash flow from future sales of Pulmazole.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla’s subsidiary -- Cipla Technologies LLC and Pulmatrix, I..
16Apr04-16-2019$Cipla rises with its arm inking definitive agreement with Pulmatrix Cipla rises with its arm ink

Cipla is currently trading at Rs. 566.75, up by 0.65 points or 0.11% from its previous closing of Rs. 566.10 on the BSE.

The scrip opened at Rs. 567.10 and has touched a high and low of Rs. 571.45 and Rs. 566.00 respectively. So far 7778 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 678.00 on 19-Sep-2018 and a 52 week low of Rs. 483.75 on 29-Jan-2019.

Last one week high and low of the scrip stood at Rs. 571.45 and Rs. 531.95 respectively. The current market cap of the company is Rs. 45610.75 crore.

The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 39.60% and 23.69% respectively.

Cipla’s subsidiary -- Cipla Technologies LLC and Pulmatrix, Inc., a clinical stage biopharmaceutical company has entered into a definitive agreement for the co-development and commercialization of Pulmazole (PUR1900) - an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Following the Definitive Agreement, Cipla Technologies will make an upfront payment of $22 million to Pulmatrix in exchange for assignment of all rights for Pulmazole in relation to pulmonary indications to Cipla Technologies. Thereafter, both parties will equally share costs related to the future development and commercialization of Pulmazole, and equally share worldwide free cash flow from future sales of Pulmazole.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla is currently trading at Rs. 566.75, up by 0.65 points or..
16Apr04-16-2019$Dr. Reddys Lab, Majesco and Cipla to see some action today Dr. Reddys Lab, Majesco and

Dr. Reddys Laboratories has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA), for the company’s Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad. Earlier, in February, 2019 this site has undergone an audit by the USFDA, wherein the company were issued a Form 483 with 11 observations. Based on the responses and follow up actions, the US FDA has determined the inspection classification of this facility as Voluntary Action Initiated (VAI).

Majesco has unveiled the upcoming version 11 release of the Majesco P&C Core Suite, including Majesco Policy for P&C, Majesco Billing for P&C and Majesco Claims for P&C. The new version will be generally available in October 2019.

Cipla’s subsidiary -- Cipla Technologies LLC and Pulmatrix, Inc., a clinical stage biopharmaceutical company has entered into a definitive agreement for the co-development and commercialization of Pulmazole (PUR1900) - an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Future Consumer is planning to raise funds around Rs 280 crore through issuance of debentures to Verlinvest SA and the International Finance Corporation (IFC) on a preferential basis. The objective of the proposed preferential allotment of compulsorily convertible debentures (CCDs) is to utilise the amount for the purpose of repayment of high-cost debt, capital expenditure and working capital requirements and investments in joint ventures and business alliances.

Suven Life Science’s board has approved the enhancement of investment limits in wholly owned subsidiary (WOS) in USA Suven Neurosciences, Inc. from $25 million upto $50 million to undertake clinical trials on the molecules in the pipeline. The Board of directors of the company at its meeting held on April 15, 2019 has approved for the same.

Cyient has launched a portfolio of services and solutions that help Communication Service Providers (CSPs) expedite 5G network rollouts globally. The services will help in defining the migration roadmap towards the 5G NSA standard, but also help in planning smarter and faster rollouts, including site verification and benchmarking in post deployment operations.

HPL Electric & Power has launched a new advertising campaign -‘Karo Powerplay On’. The advertisement features Shikhar Dhawan, Rishabh Pant and Prithvi Shaw of Delhi Capitals and highlights the superior features that company’s products share with these cricketers such as outstanding and powerful performance with high reliability.

Dr. Reddys Laboratories has received the Establishment Inspecti..
12Apr04-12-2019$Cipla launches Niveoli HFA inhaler for adults Cipla launches Niveoli HFA i

Cipla has launched Niveoli, India’s first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targeting drug delivery to the small airways. Niveoli is a proprietary Cipla inhaler, and the latest offering from Cipla in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD).

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla has launched Niveoli, India’s first extra-fine particle..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit2953.214685.2
Gross Profit 4115.1 19114
Operating Profit 5630.325304.3
Net Sales 28352114448.1
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Dr. Reddys Lab (BSE)
 2924.15 (2.41%)
M.Cap ( in Cr)
48560.17
Jenburkt Pharma (BSE)
 496.40 (2.60%)
M.Cap ( in Cr)
227.82
Aurobindo Pharma (BSE)
 795.60 (1.41%)
M.Cap ( in Cr)
46615.45
Astrazeneca Pharma I (BSE)
 2262.85 (0.46%)
M.Cap ( in Cr)
5657.13
Everest Organics (BSE)
 204.45 (5.01%)
M.Cap ( in Cr)
163.56
Shareholding Pattern More
PROMOTERS 36.7 %
FI/BANKS/INSURANCE 3.75 %
NON-INSTITUTION 22.49 %
MUTUAL FUNDS/UTI 10.27 %
FII 0.67 %
GOVERNMENT 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested